{"id":191775,"date":"2024-06-25T18:26:03","date_gmt":"2024-06-25T23:26:03","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/neuromelanin-sensitive-mri-linked-to-psychosis-severity-in-schizophrenia"},"modified":"2024-06-25T18:26:03","modified_gmt":"2024-06-25T23:26:03","slug":"neuromelanin-sensitive-mri-linked-to-psychosis-severity-in-schizophrenia","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/neuromelanin-sensitive-mri-linked-to-psychosis-severity-in-schizophrenia","title":{"rendered":"Neuromelanin-sensitive MRI linked to psychosis severity in schizophrenia"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/neuromelanin-sensitive-mri-linked-to-psychosis-severity-in-schizophrenia2.jpg\"><\/a><\/p>\n<p>Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) contrast is associated with psychosis severity in antipsychotic-free patients with schizophrenia, according to a study published online Nov. 8 in JAMA Psychiatry.<\/p>\n<p>Kenneth Wengler, Ph.D., from Columbia University in New York City, and colleagues conducted a cross-sectional study involving 42 antipsychotic-free patients with <a href=\"https:\/\/medicalxpress.com\/tags\/schizophrenia\/\" rel=\"tag\" class=\"\">schizophrenia<\/a>, 53 antipsychotic-free individuals at clinical high risk for psychosis (CHR), and 52 matched healthy controls to replicate previous findings relating NM-MRI, a proxy measure of dopamine function, to psychosis severity. Data were also included for an external validation sample of 16 antipsychotic-naive patients with schizophrenia.<\/p>\n<p>The researchers found that higher Positive and Negative Syndrome Scale positive total scores correlated with higher mean NM-MRI contrast in the psychosis regions of interest (ROI) in the schizophrenia sample.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) contrast is associated with psychosis severity in antipsychotic-free patients with schizophrenia, according to a study published online Nov. 8 in JAMA Psychiatry. Kenneth Wengler, Ph.D., from Columbia University in New York City, and colleagues conducted a cross-sectional study involving 42 antipsychotic-free patients with schizophrenia, 53 antipsychotic-free individuals at clinical high [\u2026]<\/p>\n","protected":false},"author":661,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-191775","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/661"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=191775"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191775\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=191775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=191775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=191775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}